Tumor News and Research

RSS

Understanding mechanism of SIRT6 activity may help treat diabetes and cancer

A study investigating how a cellular enzyme affects blood glucose levels in mice provides clues to pathways that may be involved in processes including the regulation of longevity and the proliferation of tumor cells.

22 Jan 2010

Molecular image guided system for diagnosis and treatment of small-cell peripheral lung cancer

Scientists at The Methodist Hospital Research Institute in Houston received a research grant from the Cancer Prevention Research Institute of Texas (CPRIT) today to develop the first molecular image guided system to diagnose and treat small-cell peripheral lung cancer in one sitting.

22 Jan 2010

Mice study shows obesity can increase risk of developing liver cancer

Obesity comes with plenty of health risks, but there's one that's perhaps not so well known: an increased risk of developing cancer, and especially certain types of cancer like liver cancer. Now, a group of researchers reporting in the January 22nd issue of the journal Cell, a Cell Press publication, have confirmed in mice that obesity does indeed act as a "bona fide tumor promoter." They also have good evidence to explain how that happens.

22 Jan 2010

World’s first Cs-131 implant for colorectal cancer performed at Weill Cornell Medical Center

IsoRay, Inc., announced today that on October 10, 2009, Dr. Bhupesh Parashar, Dr. A Gabriella Wernicke and Dr. KS Clifford Chao from the Department of Radiation Oncology, and Dr. Jeffery Milsom from the Department of Gastrointestinal Surgery, at Weill Cornell Medical Center performed the world’s first Cesium-131(Cs-131) implant for the treatment of colorectal cancer.

21 Jan 2010

COTI's novel small molecule effective against pancreatic cancer in animal model

Critical Outcome Technologies Inc. announced more positive results today from animal experiments carried out at a prominent Canadian cancer research facility. This new series of experiments adds to the impressive data package for COTI-2, demonstrating efficacy both as a single agent and in combination with current first line therapies, as well as low toxicity in several different animal models of human cancers.

21 Jan 2010

IMUC’s ICT-107 vaccine product candidate targets cancer stem cells

ImmunoCellular Therapeutics today announced the results of a study in which it was shown that certain specific antigens are highly expressed on cancer stem cells (CSCs). This suggests that IMUC’s lead cancer vaccine product candidate ICT-107, which targets those antigens, may effectively target not only the cells that make up the bulk of certain cancerous tumors, but also the CSCs that are widely believed to give rise to them and cause their recurrence.

21 Jan 2010

Medical student receives 2009 Lucien Rubenstein Award

The American Brain Tumor Association has announced that Alexander Ksendzovsky, a third-year medical student at the Chicago Medical School of Rosalind Franklin University in North Chicago, is the 2009 Lucien Rubenstein Award recipient.

21 Jan 2010

Medco Health Solutions launches Medco TRC for oncology patients

Medco Health Solutions, Inc. today announced the launch of the Medco Therapeutic Resource Center® (TRC) for oncology patients headquartered in Whitestown, Ind., where specialist pharmacists will manage the company's more than 850,000 patients currently living with cancer, one of the fastest growing segments of healthcare.

21 Jan 2010

Research provides new insights on VEGF receptor function

Researchers at the University of Helsinki, Finland, and the Paul Scherrer Institute (PSI) in Villigen, Switzerland, have determined the crystal structure of the ligand binding domain of a vascular endothelial growth factor (VEGF) receptor in complex with one of its ligands (VEGF-C).

21 Jan 2010

Gene study could result in personalized therapies for patients with deadly brain cancer

New findings by researchers at UNC Lineberger Comprehensive Cancer Center suggest that the most common form of malignant brain cancer in adults, glioblastoma multiforme (GBM), is probably not a single disease but a set of diseases, each with a distinct underlying molecular disease process.

20 Jan 2010

TCGA study reveals four distinct molecular subtypes of GBM

The most common form of malignant brain cancer in adults, glioblastoma multiforme (GBM), is not a single disease but appears to be four distinct molecular subtypes, according to a study by the Cancer Genome Atlas (TCGA) Research Network. The researchers of this study also found that response to aggressive chemotherapy and radiation differed by subtype.

20 Jan 2010

Scientists study fruit fly to identify key molecular signal in cancer metastasis

Scientists trying to understand how cancer cells invade healthy tissue have used the fruit fly's metamorphosis from maggot to flying insect as a guide to identify a key molecular signal that may be involved in both processes.

20 Jan 2010

New minimally invasive surgery for lung cancer reduces post-operative pain

Generally, after traditional open-chest surgery for lung cancer, patients may experience a significant amount of pain and spend up to a week in the hospital followed by months recovering.

20 Jan 2010

New heating therapy reduces mastectomies, kills large tumors

A new treatment developed and tested by University of Oklahoma researchers not only killed large breast cancer tumors, but reduced the need for mastectomies by almost 90 percent. The latest results appear in an upcoming issue of the Annals of Surgical Oncology.

20 Jan 2010

Researchers show how gliomas can evade drugs aimed at blocking EGFR

Researchers at the Ludwig Institute for Cancer Research (LICR) at the University of California, San Diego School of Medicine and Moores UCSD Cancer Center have shown one way in which gliomas, a deadly type of brain tumor, can evade drugs aimed at blocking a key cell signaling protein, epidermal growth factor receptor (EGFR),that is crucial for tumor growth.

20 Jan 2010

Fc engineering enhances antibody half-life

A Nature Biotechnology article published online January 17 reveals that Xencor Inc.’s proprietary Fc engineering extends the half-life of antibodies while maintaining their potency and extending duration of action. These results, published in an article entitled, “Enhanced antibody half-life improves in vivo activity” demonstrate the potential of Fc engineering to impact the flexibility of route, schedule and dose for nearly any antibody.

20 Jan 2010

Alnylam Pharmaceuticals presents data on multiple therapeutic programs at RNAi Symposium

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced that it presented data from multiple pre-clinical and clinical programs at the “RNA Silencing: Mechanism, Biology, and Application” Keystone Symposium held January 14-19, 2010 in Keystone, Colorado. Alnylam and its collaborators presented data from Alnylam’s therapeutic programs including transthyretin (TTR)-mediated amyloidosis and Huntington’s disease, as well as new data on delivery approaches for the systemic delivery of RNAi therapeutics.

20 Jan 2010

Combination treatment strategies may benefit patients with non-small cell lung cancer

Even when their tumors are shrinking in response to therapy, some non-small cell lung cancer (NSCLC) patients have a scattering of cancer cells that are undeterred by the drug, causing the tumor to resume its growth, Dana-Farber Cancer Institute and Massachusetts General Hospital (MGH) Cancer Center scientists report in the January issue of Cancer Cell.

20 Jan 2010

New research at Rhode Island Hospital identifies a treatment for glioblastomas

New research at Rhode Island Hospital has identified a treatment in animal models for glioblastomas - deadly brain tumors which, once diagnosed, offer a poor prognosis and relatively short life expectancy.

20 Jan 2010

Study shows an intriguing relationship between cancer-related genes and schizophrenia susceptibility

People who inherit a specific form of a gene that puts them on a road to schizophrenia may be protected against some forms of cancer, according to a new study by scientists at The Feinstein Institute for Medical Research.

20 Jan 2010